OBJECTIVE: To explore the clinical effects of escitalopram combined with dopasin on patients with Parkinson’s disease and its effects on inflammatory factors. METHODS: Totally 138 patients with Parkinson‘s disease admitted into Jingzhou the First People’s Hospital from Apr. 2018 to Dec. 2019 were extracted to be divided into the control group and the observation group

with 69 cases in each group. The control group was treated with dopasizide

while the observation group received escitalopram on the basis of the control group. Hamilton depression scale（ HAMD）

unified Parkinson’s disease rating scale（ UPDRS）

Hamilton anxiety scale（ HAMA） and Wechsler memory scale（ WMS） scores

inflammation factor levels

clinical efficacy and adverse drug reactions of two groups were observed. RESULTS: HAMD

UPDRS and HAMA scores of the observation group were significantly lower than those of the control group

WMS scores were significantly higher than those of the control group

and inflammatory factors were significantly lower than those of the control group

the differences were statistically significant（ P <0. 05）. The total effective rate in the observation group was 95. 65%（ 66/69）

significantly higher than 82. 61%（ 57/69） in the control group

with statistically significant difference（ P < 0. 05）. The incidence of adverse drug reactions in the observation group was 11. 59%（ 8/69）

slightly higher than that in the control group 7. 25%（ 5/69）

yet the difference was not statistically significant（ P > 0. 05）. CONCLUSIONS: Escitalopram combined with dopamine can effectively improve the clinical symptoms of patients with Parkinson’s disease

inhibit the inflammatory response and repair damaged nerves.